NCT03515629View on ClinicalTrials.gov

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

PHASE3TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 2, 2018

Primary Completion Date

July 29, 2021

Study Completion Date

July 29, 2021

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

REGN2810/ipi

REGN2810 plus ipilimumab

DRUG

REGN2810/chemo/ipi

REGN2810 plus chemotherapy plus Ipilimumab

DRUG

Pembrolizumab

Reference drug administered IV infusion

Trial Locations (3)

26100

Regeneron Research Site, Cremona

33709

Regeneron Research Site, St. Petersburg

08660

Regeneron Research Site, Vilnius

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY